REGN vs SDGR
Regeneron Pharmaceuticals Inc (REGN) versus Schrodinger Inc (SDGR) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Schrodinger Inc (SDGR) is a health information services company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SDGR revenue for 2024-12-31 was $207.5M. Net income was -$187.1M. Revenue was down 4.2% from 2023-12-31 to 2024-12-31. SDGR currently screens at market cap $1.16B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SDGR currently screens at market cap $1.16B.
Not investment advice. Open the REGN and SDGR stock pages for the full models.
Not investment advice.